Dear Reader,

As we reach the final issue of *Drugs---Real World Outcomes* for 2019, we wish to reflect on another successful year's achievements, and to thank all those who have contributed their time and effort to guarantee the high quality of our content.

2019 was a successful year for *Drugs---Real World Outcomes*. Over 20 articles have been published; the most popular of these, in terms of downloads from SpringerLink, have been:Adverse Events Associated with Risperidone Use in Pediatric Patients: A Retrospective Biobank Study. Oshikoya, K.A., Carroll, R., Aka, I. et al. Drugs---Real World Outcomes (2019) 6: 59. 10.1007/s40801-019-0151-7Patterns of High-Dose and Long-Term Proton Pump Inhibitor Use: A Cross-Sectional Study in Six South Australian Residential Aged Care Services. Hendrix, I., Page, A.T., Korhonen, M.J. et al. Drugs---Real World Outcomes (2019) 6: 105. 10.1007/s40801-019-0157-1Use of a Healthcare Claims Database for Post-Marketing Safety Assessments of Eribulin in Japan: A Comparative Assessment with a Prospective Post-Marketing Surveillance Study. Sakata, Y., Matsuoka, T., Ohashi, S. et al. Drugs---Real World Outcomes (2019) 6: 27. 10.1007/s40801-019-0150-8Characterization of Patients with Ankylosing Spondylitis Receiving Secukinumab and Reasons for Initiating Treatment: A US Physician Survey and Retrospective Medical Chart Review. Joshi, R., Latremouille-Viau, D., Meiselbach, M.K. et al. Drugs---Real World Outcomes (2019) 6: 1. 10.1007/s40801-018-0146-9A Benefit Risk Review of Pediatric Use of Hydrocodone/Chlorpheniramine, a Prescription Opioid Antitussive Agent for the Treatment of Cough. Sloan, V.S., Jones, A., Maduka, C. et al. Drugs---Real World Outcomes (2019) 6: 47. 10.1007/s40801-019-0152-6Epidemiological Profile of Drug Overdose Reported in South-East Morocco from 2004 to 2016. Azekour, K., Belamalem, S., Soulaymani, A. et al. Drugs---Real World Outcomes (2019) 6: 11. 10.1007/s40801-019-0148-2Re-evaluating Safety and Effectiveness of Dabigatran Versus Warfarin in a Nationwide Data Environment: A Prevalent New-User Design Study. Lin, HM.D., Lai, CL., Dong, YH. et al. Drugs---Real World Outcomes (2019) 6: 93. 10.1007/s40801-019-0156-2PEARL: A Non-interventional Study of Real-World Alirocumab Use in German Clinical Practice. Parhofer, K.G., von Stritzky, B., Pietschmann, N. et al. Drugs---Real World Outcomes (2019) 6: 115. 10.1007/s40801-019-0158-0

We thank the authors who have contributed articles to *Drugs*---*Real World Outcomes* over the course of 2019. The skill and dedication of all authors are critical to the continued publication of the journal. The quality of published articles is also testament to the significant efforts of the peer reviewers, whose commitment ensures that the journal's content is held to the highest possible standard. We would like to thank the following individuals who acted as reviewers for *Drugs*---*Real World Outcomes* in the last 12 months:
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In addition, we would like to thank the members of the journal's Honorary Editorial Board, who have acted as peer reviewers and authors, and have provided guidance on journal content, policy and processes:
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We do hope that you have found the articles published throughout the year in *Drugs*---*Real World Outcomes* to be interesting and informative. The editorial schedule for 2020 is well under way, and we are looking forward to bringing you many high-quality and authoritative articles over the coming year.

With best wishes

Dene Peters (Editor) and Kathy Fraser (Deputy Editor)
